Phase 2 Heart Disease Trial, Recruiting NCT07192211 Sponsor: Rohto Pharmaceutical Co., Ltd. Condition: Heart Disease
Back to Heart Disease

Phase 2 Heart Disease Trial, Recruiting

NCT07192211
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with long-term heart failure caused by reduced blood flow to the heart, and who are scheduled to have open-heart bypass surgery (a procedure to reroute blood around blocked arteries)
  • People whose heart pumping strength, measured by a heart ultrasound at the initial screening appointment, is below 40% (this measurement is called ejection fraction, and a lower number means the heart is not pumping as strongly as normal)
  • There may be additional criteria not listed here (confirm with trial site)

Who may not be able to join:

  • People who also have serious problems with their heart valves
  • People who experienced a sudden, severe heart event (such as a heart attack) within the 3 months before agreeing to join the trial
  • There may be additional exclusion criteria not listed here (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Shigeru Miyagawa, profesor, Osaka University

Phone: 81-3-6832-6014

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Rohto Pharmaceutical Co., Ltd.
Registry
ClinicalTrials.gov
Start date
28 April 2026
Est. completion
30 September 2028

Where this trial is recruiting

🇯🇵 Japan

Primary endpoints

Time to the first occurrence of the cardiovascular events

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov